Size : 500mg
Telefonnummer : +1 850 650 7790
Synonyms: 2-hydroxypropanoic acid
| Description | Lactic acid (2-hydroxypropanoic acid), a glycolysis end product, is a hydroxycarboxylic acid receptor 1 (HCAR1) activator (EC50=4.2-5 mM). Lactic acid can be used as a hemodynamic index in critically ill patients and has anti-tumor activity. |
| Targets & IC50 | GPR109A:1 mM (EC50), GPR81 (HCAR1):1 mM (EC50), GPR109B:1 mM (EC50) |
| In vitro | METHODS: : Effects on cell proliferation and migration of uveal melanoma after treatment with Lactic acid (20 mM) for 24 and 48 hours. RESULTS: Lactic acid led to a significant reduction in cell proliferation and migration. [1] Method: Uveal melanoma was treated with Lactic acid (20 mM) for 24 hours, and the protein expression level was detected by western blot. Result: Lactic acid promoted the increase in the protein expression levels of MCT1 and HCAR1. [1] |
| In vivo | METHODS: To detect the anti-tumor activity in vivo, Lactic acid (1.6 g/kg) was subcutaneously injected into Female C57BL/6 mice with MC38 colon cancer cells; pH 7.4 Once a day; From Day 8 to Day 30. RESULTS: Lactic acid demonstrated CD8+ T cell-dependent tumor growth inhibition in the MC38 colon cancer model. [2] |
| Synonyms | 2-hydroxypropanoic acid |
| Molecular Weight | 90.08 |
| Formula | C3H6O3 |
| Cas No. | 50-21-5 |
| Smiles | O=C(O)C(O)C |
| Relative Density. | 1.31g/cm3 |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (999.11 mM), Sonication is recommended. H2O: 100 mg/mL (1110.12 mM), Sonication is recommended.  | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween-80+45% Saline: 5 mg/mL (55.51 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO/H2O
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO stock solution to 400 µL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|
